Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2004 1
2005 2
2007 1
2008 2
2009 2
2010 4
2011 4
2012 5
2013 8
2014 5
2015 6
2016 7
2017 6
2018 7
2019 2
2020 7
2021 17
2022 26
2023 28
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Results by year

Filters applied: . Clear all
Page 1
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study Group. Turner NC, et al. N Engl J Med. 2023 Jun 1;388(22):2058-2070. doi: 10.1056/NEJMoa2214131. N Engl J Med. 2023. PMID: 37256976 Clinical Trial.
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Cortés J, et al. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022. N Engl J Med. 2022. PMID: 35320644 Clinical Trial.
Hereditary Cancer Syndromes: A Comprehensive Review with a Visual Tool.
Garutti M, Foffano L, Mazzeo R, Michelotti A, Da Ros L, Viel A, Miolo G, Zambelli A, Puglisi F. Garutti M, et al. Among authors: zambelli a. Genes (Basel). 2023 Apr 30;14(5):1025. doi: 10.3390/genes14051025. Genes (Basel). 2023. PMID: 37239385 Free PMC article. Review.
Potential pitfalls in the use of real-world data for studying long COVID.
Zhang HG, Honerlaw JP, Maripuri M, Samayamuthu MJ, Beaulieu-Jones BR, Baig HS, L'Yi S, Ho YL, Morris M, Panickan VA, Wang X, Weber GM, Liao KP, Visweswaran S, Tan BWQ, Yuan W, Gehlenborg N, Muralidhar S, Ramoni RB; Consortium for Clinical Characterization of COVID-19 by EHR (4CE); Kohane IS, Xia Z, Cho K, Cai T, Brat GA. Zhang HG, et al. Nat Med. 2023 May;29(5):1040-1043. doi: 10.1038/s41591-023-02274-y. Nat Med. 2023. PMID: 37055567 Free PMC article. No abstract available.
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors.
Zattarin E, Presti D, Mariani L, Sposetti C, Leporati R, Menichetti A, Corti C, Benvenuti C, Fucà G, Lobefaro R, Ligorio F, Provenzano L, Vingiani A, Del Vecchio M, Griguolo G, Sirico M, Bernocchi O, Marra A, Zagami P, Agostinetto E, Jacobs F, Di Mauro P, Esposito A, Giorgi CA, Lalli L, Boldrini L, Giacchetti PPB, Schianca AC, Guarneri V, Pedersini R, Losurdo A, Zambelli A, Generali D, Criscitiello C, Curigliano G, Pruneri G, de Braud F, Dieci MV, Vernieri C. Zattarin E, et al. Among authors: zambelli a. NPJ Breast Cancer. 2023 Apr 17;9(1):27. doi: 10.1038/s41523-023-00534-1. NPJ Breast Cancer. 2023. PMID: 37069173 Free PMC article.
Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer.
Jacobs F, Agostinetto E, Miggiano C, De Sanctis R, Zambelli A, Santoro A. Jacobs F, et al. Among authors: zambelli a. Cancers (Basel). 2023 May 26;15(11):2933. doi: 10.3390/cancers15112933. Cancers (Basel). 2023. PMID: 37296893 Free PMC article. Review.
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial.
Malorni L, Bianchini G, Caputo R, Zambelli A, Puglisi F, Bianchi GV, Del Mastro L, Paris I, Montemurro F, Allegrini G, Colleoni M, Tamberi S, Zamagni C, Cazzaniga ME, Orditura M, Guarneri V, Castelletti D, Benelli M, Di Marino M, Arpino G, De Laurentiis M. Malorni L, et al. Among authors: zambelli a. Eur J Cancer. 2023 Jun;186:1-11. doi: 10.1016/j.ejca.2023.03.001. Epub 2023 Mar 8. Eur J Cancer. 2023. PMID: 37003098 Free article. Clinical Trial.
Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment.
Tinterri C, Canavese G, Gatzemeier W, Barbieri E, Bottini A, Sagona A, Caraceni G, Testori A, Di Maria Grimaldi S, Dani C, Boni L, Bruzzi P, Fernandes B, Scorsetti M, Zambelli A, Gentile D; SINODAR-ONE Collaborative Group. Tinterri C, et al. Among authors: zambelli a. Br J Surg. 2023 Aug 11;110(9):1143-1152. doi: 10.1093/bjs/znad215. Br J Surg. 2023. PMID: 37471574 Free PMC article. Clinical Trial.
133 results